Displaying drugs 7726 - 7750 of 8109 in total
3'-O-Acetylthymidine-5'-diphosphate
Experimental
Mercaptocarboxylate Inhibitor
Experimental
Sorbinil
Experimental
Investigational
Z-Pro-Prolinal
Experimental
Reglitazar
Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.
Investigational
VX-702
VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.
Investigational
Cobiprostone
Investigational
Tanomastat
Investigational
Enzastaurin
Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.
Investigational
BMS-564929
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
Haloxyfop-P
Experimental
Displaying drugs 7726 - 7750 of 8109 in total